Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

ClinicalTrials.gov ID: NCT01888874

Public ClinicalTrials.gov record NCT01888874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram \[mg\], 100 mg and 200 mg daily -, each evaluated as once daily \[QD\] and twice daily \[BID\] regimen) or matching placebo for 24 weeks. •During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses and dose regiments of GLPG0634 administration on participants' disability, fatigue, and quality of life were evaluated.

Study identification

NCT ID
NCT01888874
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Enrollment
599 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 16, 2013
Primary completion
Feb 17, 2015
Completion
May 13, 2015
Last update posted
Nov 16, 2020

2013 – 2015

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Rheumatology Associates of North Alabama, PC Huntsville Alabama
Artho Care, Arthritis Care & Research P.C. Gilbert Arizona
Arizona Arthritis & Rheumatology Research PLLC Phoenix Arizona
C.V. Mehta MD Medical Corporation Hemet California
Center for Innovative TherapyDivision of Rheumatology, UCSD La Jolla California
Desert Medical Advances Palm Desert California
Desert Valley Medical Center Victorville California
Infosphere Clinical Research, Inc. West Hills California
RASF Clinical Research Center Boca Raton Florida
Millennium Research Ormond Beach Florida
Lovelace Scientific Resources Venice Florida
Arthritis Center of North GA Gainesville Georgia
Idaho Arthritis Center Meridian Idaho
The Arthritis Center Springfield Illinois
Professional Research Network of Kansas Wichita Kansas
Arthritis Treatment Center Frederick Maryland
Klein and Associates MD Hagerstown Maryland
Private practice Lansing Michigan
Mayo Clinic Rochester Minnesota
Physicians East Greenville North Carolina
Health Research of Oklahoma Oklahoma City Oklahoma
Altoona Center Clinical Research Duncansville Pennsylvania
Austin Rheumatology Research PA Austin Texas
Arthritis Centers of Texas Dallas Texas
Pioneer Research Solutions Inc Houston Texas
Crossroads Clinical Research, LLC Victoria Texas
Seattle Rheumatology Associates, PLLC Seattle Washington
Mountain State Clinical Research Clarksburg West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01888874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01888874 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →